78 related articles for article (PubMed ID: 7518160)
1. Whole blood and plasma levels of FK 506 after liver transplantation: correlation with toxicity.
Bäckman L; Nicar M; Levy M; Distant D; Eisenstein C; Renard T; Goldstein R; Husberg B; Gonwa T; Klintmalm G
Transplant Proc; 1994 Jun; 26(3):1804. PubMed ID: 7518160
[No Abstract] [Full Text] [Related]
2. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients.
Winkler M; Jost U; Ringe B; Gubernatis G; Wonigeit K; Pichlmayr R
Transplant Proc; 1991 Dec; 23(6):3153-5. PubMed ID: 1721389
[No Abstract] [Full Text] [Related]
3. Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation.
Winkler M; Ringe B; Jost U; Gubernatis G; Pichlmayr R
Transplant Proc; 1993 Aug; 25(4):2688-90. PubMed ID: 7689277
[No Abstract] [Full Text] [Related]
4. FK 506 treatment of intractable rejection after liver transplantation.
Jost U; Winkler M; Ringe B; Rodeck B; Pichlmayr R
Transplant Proc; 1993 Aug; 25(4):2686-7. PubMed ID: 7689276
[No Abstract] [Full Text] [Related]
5. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity.
Assan R; Fredj G; Larger E; Feutren G; Bismuth H
Diabete Metab; 1994; 20(1):49-52. PubMed ID: 7520007
[TBL] [Abstract][Full Text] [Related]
6. Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine.
Park KM; Hay JE; Lee SG; Lee YJ; Wiesner RH; Porayko MK; Krom RA
Transplant Proc; 1996 Jun; 28(3):1738-40. PubMed ID: 8658863
[No Abstract] [Full Text] [Related]
7. Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group.
Bäckman L; Levy MF; Klintmalm G
Transplant Proc; 1995 Feb; 27(1):1124. PubMed ID: 7533361
[No Abstract] [Full Text] [Related]
8. Chronic nephrotoxicity of FK 506 after liver transplantation.
Bäckman L; Nicar M; Levy M; Distant D; Eisenstein C; Renard T; Goldstein R; Husberg B; Gonwa T; Klintmalm G
Transplant Proc; 1994 Jun; 26(3):1803. PubMed ID: 7518159
[No Abstract] [Full Text] [Related]
9. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
[TBL] [Abstract][Full Text] [Related]
10. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization.
Schwartz M; Holst B; Facklam D; Buell D
Transplant Proc; 1995 Feb; 27(1):1107. PubMed ID: 7533355
[No Abstract] [Full Text] [Related]
11. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
Klintmalm GB; Goldstein R; Gonwa T; Wiesner RH; Krom RA; Shaw BW; Stratta R; Ascher NL; Roberts JW; Lake J
Transplant Proc; 1993 Feb; 25(1 Pt 1):679-88. PubMed ID: 7679840
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus (FK 506) given three times daily after liver transplantation for minimizing nephrotoxicity and neurotoxicity.
Khalaf H; Al-Asseri A; Bhuiyan J; Nafea O; Al-Sebayel M
Transplant Proc; 2003 Nov; 35(7):2787-8. PubMed ID: 14612120
[No Abstract] [Full Text] [Related]
13. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients.
Porayko MK; Textor SC; Krom RA; Hay JE; Gores GJ; Wahlstrom HE; Sanchez-Urdazpal L; Richards T; Crotty P; Beaver S
Transplant Proc; 1993 Feb; 25(1 Pt 1):665-8. PubMed ID: 7679835
[No Abstract] [Full Text] [Related]
14. Monitoring FK 506 concentrations in plasma and whole blood.
Jusko WJ; D'Ambrosio R
Transplant Proc; 1991 Dec; 23(6):2732-5. PubMed ID: 1721260
[TBL] [Abstract][Full Text] [Related]
15. The use of plasma levels for FK 506 dosing in liver-grafted patients.
Winkler M; Ringe B; Rodeck B; Melter M; Stoll K; Baumann J; Wonigeit K; Pichlmayr R
Transpl Int; 1994 Aug; 7(5):329-33. PubMed ID: 7527638
[TBL] [Abstract][Full Text] [Related]
16. Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring.
Winkler M; Wonigeit K; Undre N; Ringe B; Oldhafer K; Christians U; Pichlmayr R
Transplant Proc; 1995 Feb; 27(1):822-5. PubMed ID: 7533433
[No Abstract] [Full Text] [Related]
17. A case of hyperkalemic distal renal tubular acidosis secondary to tacrolimus in living donor liver transplantation.
Oishi M; Yagi T; Urushihara N; Takakura N; Inagaki M; Sadamori H; Mastukawa H; Inoue T; Oda S; Tanaka N
Transplant Proc; 2000 Nov; 32(7):2225-6. PubMed ID: 11120143
[No Abstract] [Full Text] [Related]
18. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
Klintmalm GB; Goldstein R; Gonwa T; Wiesner RH; Krom RA; Shaw BW; Stratta R; Ascher NL; Roberts JW; Lake J
Transplant Proc; 1993 Feb; 25(1 Pt 1):641-3. PubMed ID: 7679828
[No Abstract] [Full Text] [Related]
19. Therapeutic monitoring of tacrolimus concentrations in blood of renal and liver transplant recipients: comparison of microparticle enzyme immunoassay and enzyme multiplied immunoassay methods.
Bartlomiejczyk I; Zochowska D; Sanko-Resmer J; Matuszewicz D; Paczek L
Transplant Proc; 2006; 38(1):94-6. PubMed ID: 16504673
[TBL] [Abstract][Full Text] [Related]
20. Conversion to rescue therapy with FK 506: data from eight liver transplant patients.
Reggiani P; Orsenigo R; Gatti S; Albani AP; Ferla G; Doglia M; Fassati LR; Galmarini D
Transplant Proc; 1994 Dec; 26(6):3597-8. PubMed ID: 7527982
[No Abstract] [Full Text] [Related]
[Next] [New Search]
